GSK2878175 News - LARVOL Sigma

|||||||||| GSK2878175 / GSK
Clinical, Journal: Randomized Clinical Trials Towards a Single-Visit Cure for Chronic Hepatitis C: Oral GSK2878175 and Injectable RG-101 in Chronic Hepatitis C Patients and Long-Acting Injectable GSK2878175 in Healthy Participants. (Pubmed Central) - Aug 13, 2021
In conclusion, single injection of RG-101 combined with 12 weeks of GSK2878175 oral tablets was generally well tolerated and resulted in high SVR rates in chronic hepatitis C patients. Single injections of GSK2878175 long-acting injectable were also well tolerated, however, higher doses would be required if used in combination with RG-101 to achieve the SVR rates observed in the oral combination study to enable a single-visit curative regimen.

||||||||||  GSK2878175 / GSK
Trial completion:  Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C. (clinicaltrials.gov) -  Sep 16, 2015
P1, N=37, Completed,  Sponsor: GlaxoSmithKline
Single injections of GSK2878175 long-acting injectable were also well tolerated, however, higher doses would be required if used in combination with RG-101 to achieve the SVR rates observed in the oral combination study to enable a single-visit curative regimen. Active, not recruiting --> Completed

||||||||||  GSK2878175 / GSK
Enrollment closed, Enrollment change, Trial primary completion date:  Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C. (clinicaltrials.gov) -  Aug 19, 2014
P1, N=8, Active, not recruiting,  Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=44 --> 8 | Trial primary completion date: Apr 2014 --> Jul 2014

||||||||||  GSK2878175 / GSK
Enrollment open:  Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C. (clinicaltrials.gov) -  Mar 5, 2014
P1, N=44, Recruiting,  Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | N=44 --> 8 | Trial primary completion date: Apr 2014 --> Jul 2014 Not yet recruiting --> Recruiting

||||||||||  GSK2878175 / GSK
Enrollment change:  A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single & Repeat Escalating Doses of GSK2878175 in Healthy Subjects (clinicaltrials.gov) -  Feb 5, 2014
P1, N=46, Completed,  Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting N=66 --> 46

||||||||||  GSK2878175 / GSK
Trial completion:  A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single & Repeat Escalating Doses of GSK2878175 in Healthy Subjects (clinicaltrials.gov) -  Feb 5, 2014
P1, N=46, Completed,  Sponsor: GlaxoSmithKline
N=66 --> 46 Recruiting --> Completed



	Diseases Companies Products Productz Mechanisms of Action Sites